[1]BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2]TUO JY,ZHANG M,ZHENG RS,et al.Report of cancer incidence and mortality in China,2014［J］.Chinese Journal of Oncology,2018,40(1):5-11.
[3]SIEGEL RL,MILLER KD,JEMAL A,et al.Cancer statistics,2019［J］.CA Cancer J Clin,2019,69(1):7-34.
[4]COHEN PA,JHINGRAN A,OAKNIN A,et al.Cervical cancer［J］.Lancet,2019,393(10167):169-182.
[5]SMALL W,BACON MA,BAJAJ A,et al.Cervical cancer:a global health crisis［J］.Obstetrical and Gynecological Survey,2017,72(11):654-655.
[6]DUK JM,GROENIER KH,BRUIJN HWAD,et al.Pretreatment serum squamous cell carcinoma antigen:A newly identified prognostic factor in early-stage cervical carcinoma［J］.Journal of Clinical Oncology,1996,14(1):111-118.
[7]GADDUCCI A,TANA R,COSIO S,et al.The serum assay of tumour markers in the prognostic evaluation,treatment monitoring and follow-up of patients with cervical cancer:A review of the literature［J］.Crit Rev Oncol Hematol,2008,66(1):10-20.
[8]HAMADA K,ZHANG T,DESAKI J,et al.Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus［J］.Journal of Gene Medicine,2010,12(6):545-554.
[9]OGINO I,NAKAYAMA H,KITAMURA T,et al.The curative role of radiotherapy in patients with isolated para-aortic node recurrence from cervical cancer and value of squamous cell carcinoma antigen for early detection［J］.International Journal of Gynecologic Cancer,2005,15(4):630-638.
[10]KATO H,TORIGOE T.Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma［J］.Cancer,1977,40(4):1621-1628.
[11]CHOI KH,YU M,JEONG S,et al.Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis［J］.Int J Clin Oncol,2020,25(7):1405-1411.
[12]WANG XJ,SAN Q,WANG YM,et al.Value and significance of tumor markers as CEA,CA125,SCC-Ag,CA199 and CYFRA21-1 in the diagnosis of cervical cancer［J］.Journal of Hainan Medical University,2017,23(18):132-135.
[13]ZHENG SL,LI RX,LIANG JY,et al.Serum miR-638 combined with squamous cell carcinoma-related antigen as potential screening biomarkers for cervical squamous cell carcinoma［J］.Genet Test Mol Bioma,2020,24(4):188-194.
[14]GAARENSTROOM KN,BONFRER JM,KENTER GG,et al.Clinical value of pretreatment serum Cyfra 21-1,tissue polypeptide antigen,and squamous cell carcinoma antigen levels in patients with cervical cancer［J］.Cancer,1995,76(5):807-813.
[15]吕晓娟，俞华，陈鲁．宫颈癌腹主动脉旁淋巴结转移的危险因素分析［J］．现代实用医学，2011，23(8)：917-918.
LYU XJ,YU H,CHEN L.Analysis of risk factors for cervical lymph node metastasis to abdominal aorta［J］.Modern Practical Medicine,2011,23(8):917-918.
[16]LANDE JVD,DAVELAAR EM,MENSDORFF-POUILLY SV,et al.SCC-Ag,lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer［J］.Gynecologic Oncology,2009,112(1):119-125.
[17]FAN X,YANFANG L,LIANGSHENG F,et al.Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage.［J］.Journal of Cancer,2018,9(9):1660-1666.
[18]ZHOU Z,LI W,ZHANG F,et al.The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer:A meta-analysis and literature review［J］.PLoS One,2017,12(12):e0186165.
[19]MICHELA SALVATICI,MARIA T ACHILARRE,MARIA T SANDRI,et al.Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients:role in the early diagnosis of recurrence［J］.Gynecol Oncol,2016,142(1):115-119.
[20]XU D,WANG D,WANG S,et al.Correlation between squamous cell carcinoma antigen level and the clinicopathological features of early-stage cervical squamous cell carcinoma and the predictive value of squamous cell carcinoma antigen combined with computed tomography scan for lymph node metastasis［J］.Int J Gynecol Cancer,2017,27(9):1935-1942.
[21]SALANI R,KHANNA N,FRIMER M,et al.An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies:Society of Gynecologic Oncology (SGO) recommendations［J］.Gynecol Oncol,2017,146(1):3-10.
[22]YE S,SUN X,KANG B,et al.The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay:a prospective observational study［J］.BMC Cancer,2020,20(1):138.
[23]ELIT L,FYLES AW,OLIVER TK,et al.Follow-up for women after treatment for cervical cancer［J］.Current Oncology,2010,17(3):65-69.
[24]DUYN A,VAN EIJKEREN M,KENTER G,et al.Recurrent cervical cancer:detection and prognosis［J］.Acta Obstet Gynecol Scand,2002,81(8):759-763.
[25]JEONG BK,CHOI DH,HUH SJ,et al.The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix［J］.Radiation Oncology Journal,2011,29(3):191-198.
[26]JEONG BK,HUH SJ,CHOI DH,et al.Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer［J］.Cancer Research & Treatment,2013,45(1):48-54.
[27]KOTARO S,SEIJI M,TAKESHI Y,et al.Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice［J］.Journal of Gynecologic Oncology,2013,24(4):321-329.
[28]LEHTOVIRTA P,VIINIKKA L,YLIKORKALA O.Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix［J］.Gynecologic Oncology,1990,37(2):276-278.
[29]SCAMBIA G,PANICI PB,BAIOCCHI G,et al.The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy［J］.American Journal of Obstetrics & Gynecology,1991,164(4):631-636.
[30]LIU Z,SHI H.Prognostic role of squamous cell carcinoma antigen in cervical cancer:A Meta-analysis［J］.Disease Markers,2019,2019:1-10.
[31]CHARAKORN C,THADANIPON K,CHAIJINDARATANA S,et al.The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma:a systematic review and meta-analysis［J］.Gynecol Oncol,2018,150(1):190-200.
[32]KOH WJ,ABU-RUSTUM NR,BEAN S,et al.Cervical cancer,version 3.2019,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Cancer Netw,2019,17(1):64-68.
[33]KYU HYE CHOI,SEA WON LEE,MINA YU,et al.Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy:a multi-institutional analysis［J］.Gynecol Oncol,2019,30(1):e1.
[34]WANG Y,CUI T,DU L,et al.The correlation between the serum squamous carcinoma antigen and the prognosis of recurrent cervical squamous carcinoma［J］.Journal of Clinical Laboratory Analysis,2017,31(1):1-5.
[35]OH J,BAE JY.Optimal cut of level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance［J］.Obstet Gynecol Sci,2018,61(3):337-343.
[36]KUBIK S,MOSZYNSKA-ZIELINSKA M,FIJUTH J,et al.Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse［J］.Menopausal Review,2019,18(1):23-26.
[37]GUO Q,ZHU J,WU Y,et al.Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery:A single-institution study［J］.Eur J Surg Oncol,2020,46(1):131-138.